San Jose, California-based Outset said in a news release that it received the first-ever CMS approval for a Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES). The decision helps encourage healthcare providers to embrace new technology that allows for patients to dialyze at home, according to Outset.
CMS recently enacted the TPNIES program to increase access to new and innovative medical technologies for end-stage renal disease (ESRD) patients. The add-on payment addresses barriers in the ESRD bundled payment system that can discourage providers from adopting new technologies on themarket.
As part of the TPNIES approval, providers will have access to supplemental reimbursement over the next two years to support patients’ use of Tablo at home.
Tablo, an all-in-one platform, offers integrated water purification and the ability to deliver multiple dialysis treatment types within a compact, 35-inch unit. Tablo has two-way communication with the cloud so that data can be sent electronically and physicians can monitor patients remotely while they undergo dialysis treatment at home.
“For too long ESRD patients have faced a lack of innovation and options for their kidney treatment, restricting how, when and where they dialyze,” Outset Medical CEO Leslie Trigg said in the release. “At Outset, we have always believed that dialyzing at home is vital to restoring identity, autonomy and a sense of self-worth for those managing kidney disease. Today’s news is a victory for innovation and patient choice.”